Literature DB >> 17399949

Abl functions as a negative regulator of Met-induced cell motility via phosphorylation of the adapter protein CrkII.

Angel Cipres1, Yama A Abassi, Kristiina Vuori.   

Abstract

HGF, the ligand for the Met receptor tyrosine kinase, is a potent modulator of epithelial-mesenchymal transition and dispersal of epithelial cells, which are processes that play a crucial role in cell motility during normal development and malignant transformation. We and others have shown earlier that the adapter protein CrkII and its associated proteins positively regulate cell migratory events in response to both haptotactic and chemotactic stimuli, including HGF. Here, we demonstrate for the first time that phosphorylation of CrkII serves as a negative feedback loop to regulate motile responses upon Met stimulation. Thus, we found that the treatment of cells with HGF induces tyrosine phosphorylation of CrkII at Y221, which in turn results in inhibition of CrkII signaling via formation of an intramolecular pY221-SH2-domain interaction. Accordingly, expression of a mutant form of CrkII, CrkII-Y221F, which is resistant to phosphorylation at this negative regulatory site, enhanced Met-induced cell motility. Furthermore, we demonstrate here that the Met-induced CrkII phosphorylation depends on the Abl tyrosine kinase activity. As a corollary, we found that Abl inhibitors, such as the STI571 compound, significantly enhanced Met-induced cell motility, but failed to do so in cells that expressed the CrkII-Y221F mutant protein. Taken together, these results demonstrate that the Abl tyrosine kinase functions as a negative regulator of Met-induced cell migration, and that it does so by inducing CrkII phosphorylation at the site Y221.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17399949     DOI: 10.1016/j.cellsig.2007.02.011

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  10 in total

1.  Domain cooperativity in multidomain proteins: what can we learn from molecular alignment in anisotropic media?

Authors:  Tairan Yuwen; Carol Beth Post; Nikolai R Skrynnikov
Journal:  J Biomol NMR       Date:  2011-09-27       Impact factor: 2.835

2.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

3.  Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation.

Authors:  J Zheng; K Machida; S Antoku; K Y Ng; K P Claffey; B J Mayer
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

4.  Hepatocyte growth factor triggers distinct mechanisms of Asef and Tiam1 activation to induce endothelial barrier enhancement.

Authors:  Katherine Higginbotham; Yufeng Tian; Grzegorz Gawlak; Nurgul Moldobaeva; Alok Shah; Anna A Birukova
Journal:  Cell Signal       Date:  2014-08-04       Impact factor: 4.315

5.  Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.

Authors:  D Mokhtari; A Al-Amin; K Turpaev; T Li; O Idevall-Hagren; J Li; A Wuttke; R G Fred; P Ravassard; R Scharfmann; A Tengholm; N Welsh
Journal:  Diabetologia       Date:  2013-03-05       Impact factor: 10.122

6.  STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.

Authors:  Duen-Yi Huang; Yee Chao; Ming-Hui Tai; Yang-Hao Yu; Wan-Wan Lin
Journal:  J Biomed Sci       Date:  2012-03-30       Impact factor: 8.410

7.  Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility.

Authors:  Ran Li; Jennifer F Knight; Morag Park; Ann Marie Pendergast
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

8.  Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.

Authors:  Zannel Blanchard; Nicole Mullins; Pavani Ellipeddi; Janice M Lage; Shawn McKinney; Rana El-Etriby; Xu Zhang; Raphael Isokpehi; Brenda Hernandez; Wael M Elshamy
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

9.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

Review 10.  Crk and CrkL as Therapeutic Targets for Cancer Treatment.

Authors:  Taeju Park
Journal:  Cells       Date:  2021-03-27       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.